Maven Securities’s Procept Biorobotics PRCT Stock Holding History

Maven Securities’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,143	Closed	-$273K	–	1105
2021 Q3	$273K	Buy	+7,143	New	+$274K	0.01%	861

Other funds holding PRCT

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities's PRCT Position: Q4 2021 in Review

Maven Securities sold out of Procept Biorobotics (PRCT) in Q4 2021, closing a stake of 7,143 shares — an estimated $273K sold.

Maven Securities first reported a position in PRCT in Q3 2021 and held it in 1 quarter. The position peaked at $273K in Q3 2021. 60 funds tracked by Wall St. Rank hold PRCT as of Q4 2021.

Maven Securities reported no remaining Procept Biorobotics position as of Q4 2021 after selling out during the quarter.
Maven Securities sold 7,143 Procept Biorobotics shares in Q4 2021, an estimated $273K.
Maven Securities first reported a position in Procept Biorobotics in Q3 2021 and held it in 1 quarter.
Maven Securities's Procept Biorobotics position peaked at $273K in Q3 2021.
60 funds tracked by Wall St. Rank held Procept Biorobotics as of Q4 2021.

Based on Maven Securities's 13F filing for Q4 2021, filed 14 Feb 2022.